LENZ

LENZ Therapeutics, Inc. ( LENZ ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Daniel Chevallard - CFO, Principal Financial & Accounting Officer Evert Schimmelpennink - President, CEO, Secretary & Director Shawn Olsson - Chief Commercial Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Jason Gerberry - BofA Securities, Research Division Matthew Caufield - H.C.

LENZ Therapeutics NASDAQ: LENZ reported third-quarter 2026 product revenue of $2.6 million, up 50% sequentially, as prescriptions for its presbyopia eye drop VIZZ increased following the expansion of national advertising and the launch of a telehealth channel.

Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).